Wave Life Sciences has moved its next-gen obesity therapy into Phase 2, aiming to tackle one of weight loss medicine’s biggest challenges.
The obesity drug race has largely been defined by one question: how much weight can people lose? But a growing number of researchers are asking a different one: what kind of weight are they actually losing?
Wave Life Sciences has begun dosing participants in the Phase 2a portion of its INLIGHT clinical trial for WVE-007, an investigational therapy designed to reduce body fat while preserving muscle, a combination that could become increasingly important as obesity treatments evolve beyond simply lowering the number on the scale [1].
The study marks the next stage for a program that has already shown encouraging early signals, with the company now testing whether those results can be repeated in people living with more severe obesity.
Unlike the GLP-1 medicines that have reshaped obesity care over the past few years, WVE-007 takes an entirely different biological approach. Rather than working through appetite-regulating hormones, it targets a gene linked to fat metabolism, with the goal of reducing fat stores while maintaining lean muscle.
That distinction could prove meaningful. While today’s weight loss drugs have delivered unprecedented reductions in body weight, researchers have increasingly focused on an unintended consequence: some of that weight comes from muscle as well as fat. Muscle plays a critical role in mobility, metabolic health and healthy aging, making its preservation particularly important for older adults.
Phase 1 findings gave Wave Life Sciences reason for optimism. Participants experienced reductions in total body fat, harmful visceral fat surrounding internal organs and waist circumference, while muscle mass was maintained. The treatment was also generally safe and well tolerated based on the data reported so far.
The new Phase 2a study will test whether those early findings hold up in a population with higher body mass indexes between 35 and 50, including people both with and without type 2 diabetes. Researchers will follow participants for 12 months, tracking changes in body weight, body composition, waist size, liver fat and several metabolic health markers.
Could fewer injections become another advantage?
Wave Life Sciences also believes WVE-007 may eventually offer something that many obesity medicines cannot: infrequent dosing. Based on what has been observed so far, the company believes the therapy could potentially be administered just once or twice a year. That possibility remains unproven and will need confirmation in larger clinical trials, but if successful it could offer a notable contrast to therapies that require weekly injections.
The company is not positioning WVE-007 solely as an alternative to today’s blockbuster obesity drugs, however. Instead, Wave Life Sciences plans to explore whether it can complement incretin-based therapies. Separate Phase 2 studies are expected to begin during the second half of 2026, evaluating WVE-007 alongside incretin medicines and as a maintenance therapy after patients stop taking them. Those studies aim to determine whether the treatment can help patients lose additional fat, preserve muscle during weight loss or maintain metabolic improvements after discontinuing incretin therapy. Those potential benefits have yet to be established.
Dr Paul Bolno, President and CEO of Wave Life Sciences, noted that the company’s second-quarter performance demonstrated disciplined execution across its pipeline, highlighted by the recent initiation of dosing in the Phase 2a portion of the INLIGHT obesity trial.
Bolno explained that Phase 1 clinical data had already shown substantial fat reduction, specifically targeting harmful visceral fat, without muscle loss, while offering the potential for once- or twice-yearly dosing.
Looking ahead, Bolno expressed confidence that the Phase 2a trial in individuals with higher BMI and body fat would demonstrate WVE-007’s ability to drive even greater fat loss, improve overall body composition, and deliver benefits across key cardiometabolic biomarkers like liver fat.
“In tandem with this progress, we are working expeditiously to initiate Phase 2 trials evaluating WVE-007 in combination with incretins and as post-incretin maintenance; we believe WVE-007 has the potential to transform the current obesity treatment landscape,” he added [2].
A broader RNA pipeline
Obesity is only one part of Wave Life Sciences’s development strategy. The company is also advancing WVE-006, an investigational treatment for alpha-1 antitrypsin deficiency, a rare inherited disorder that affects both the lungs and liver. Wave Life Sciences plans to meet with the US Food and Drug Administration later this summer to discuss a potential accelerated approval pathway.
Meanwhile, another experimental program, WVE-008, is being developed for a genetic form of liver disease, with a clinical trial application expected during the second half of 2026.
Financially, Wave Life Sciences reported second-quarter revenue of $2.3 million while ending June with $490.6 million in cash, cash equivalents and marketable securities. The company said its existing capital is expected to fund operations into the third quarter of 2028.
For longevity researchers, WVE-007 represents something larger than another entrant in the obesity market. As the field increasingly recognizes that healthy aging is about preserving function, therapies capable of improving body composition rather than weight alone could become an important next chapter. Whether WVE-007 can deliver on that promise remains to be seen, but the Phase 2 trial should provide one of the clearest indications yet of whether muscle-preserving fat loss can move from an intriguing idea to a clinical reality.
[1] https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-initiation-phase-2a-portion
[2] https://pulse2.com/wave-life-sciences-obesity-drug-advances-to-phase-2-with-potential-for-fat-loss-without-muscle-loss/
